相关实验视频
Updated: Jan 13, 2026

07:44
Localization of the Locus Coeruleus in the Mouse Brain
Published on: March 7, 2019
19.0K
在患有莱维体痴呆症的脑位变化:系统性审查
Anaëlle Bain1, Charlotte Tomeo2, Claire André3,4
1Clinical and Research Memory Centre of Grenoble Arc Alpin Grenoble Alpes Hospital Grenoble France.
Alzheimer's & dementia (New York, N. Y.)
|January 12, 2026
概括
早期的脑位 (LC) 变化是莱维体 (DLB) 痴呆症的关键. 腰椎功能障碍有助于DLB症状,并可能提供新的生物标志物和治疗点.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 神经成像是一种神经成像.
背景情况:
- 核心位置 (Locus Coeruleus,LC) 是大脑中诺亚上腺神经元的主要来源,对认知和兴奋至关重要.
- 在阿尔茨海默氏症和帕金森病中注意到LC退化,但其在莱维体痴呆症 (DLB) 中的作用尚不清楚.
研究的目的:
- 系统地回顾部 (LC) 在莱维体痴呆症 (DLB) 病变发生过程中的作用.
- 综合人类神经病理学,神经成像学和对α-synucleinopathy的动物研究的发现.
主要方法:
- 在遵守PRISMA指南的基础上进行系统审查.
- 包括人类神经病理学和神经成像数据.
- 包括α-synucleinopathy的动物模型.
主要成果:
- 有证据表明,DLB中LC的早期和严重变化.
- 腰椎功能障碍可能是DLB关键症状的基础,比如受损的兴奋和焦虑.
- 对神经黑色素敏感的MRI显示,即使在DLB的前期阶段,LC信号也会丧失.
结论:
- 在DLB中,LC变化是最早发生的变化之一.
- 由α-synuclein驱动的LC神经退行,影响诺亚上腺功能并导致DLB症状.
- 了解LC功能障碍可能会导致DLB的新生物标志物和症状疗法.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.2K
07:26Assessing Pupil-linked Changes in Locus Coeruleus-mediated Arousal Elicited by Trigeminal Stimulation
Published on: November 26, 2019
8.6K
相关概念视频
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Dementia
508
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
508
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801